Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
Panelist: Michael Sherman, Chief Medical Officer, Harvard Pilgrim
Panelist: C. Bernie Good, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, UPMC
Moderator: Roger Longman, CEO, Real Endpoints
April 24, 2018
Boston, MAevent >
by David Crow
Express Scripts was the last large independent pharmacy benefits manager, or PBM, in the US. A PBM acts as a middleman in negotiations between drugmakers and the payers (i.e. employers, insurers, and government), which buy medicines in the US. With its $67 billion takeover of Express Scripts, health insurer Cigna is sending a signal that it will have to get bigger to deal with the most pressing malady of US healthcare: soaring costs. By buying Express Scripts, Cigna hopes to gain more scale so it can drive a harder bargain when buying drugs and services, not just from pharmaceutical companies, but also the doctors and hospitals that provide patient care.
March 8, 2018
Financial Timesread full article >
by Steve Usdin
A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.
April 9, 2018
Recent Insightsview archive >
March 26, 2018
“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER
The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. The credibility afforded by ICER’s independent status, and its inclusion of diverse stakeholder views in constructing its cost effectiveness analyses, are leading payers and PBMs to use the analyses to establish coverage criteria, determine formulary placement and negotiate discounts from drug manufacturers.read full insight article >
February 20, 2018
Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.read full press release >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.